Literature DB >> 8420733

Epinephrine as an inotropic agent in septic shock: a dose-profile analysis.

J L Moran1, M S O'Fathartaigh, A R Peisach, M J Chapman, P Leppard.   

Abstract

OBJECTIVE: To characterize the acute actions and physiologic dose profile of epinephrine, as a single inotrope, in patients with septic shock.
DESIGN: Prospective clinical study. The relationship between epinephrine dose and cardiovascular variables was analyzed using repeated-measures analysis of variance.
SETTING: ICU in a university teaching hospital. PATIENTS: Eighteen patients with septic shock, mean age 64 +/- 8 (SD) yrs, and with a mean admission Acute Physiology and Chronic Health Evaluation (APACHE II) score of 23 (range 14 to 35).
INTERVENTIONS: Initial volume loading and the measurement of a baseline hemodynamic profile were followed by the administration of an epinephrine infusion at 3 microgram/min with subsequent increments of 3 micrograms/min and the determination of a hemodynamic profile after each dose increment. Therapy was titrated to clinical goals of perfusion and restoration of premorbid systolic arterial BP.
MEASUREMENTS AND MAIN RESULTS: After volume loading, mean hemodynamic indices were as follows: mean arterial pressure (MAP) 62 +/- 7 mm Hg; cardiac index 3.8 +/- 1.1 L/min/m2; left ventricular stroke work index 25 +/- 11 g.m/m2; oxygen delivery (Do2) index 460 +/- 168 mL/min/m2; and oxygen consumption (VO2) index 165 +/- 64 mL/min/m2. In the dose range of 3 to 18 microgram/min, epinephrine produced linear increases in average heart rate, MAP, cardiac index, left ventricular stroke work index, stroke volume index, VO2, and DO2. No effect was noted on pulmonary artery occlusion pressure (PAOP), mean pulmonary arterial pressure, or systemic vascular resistance index.
CONCLUSIONS: Epinephrine increases DO2 in septic shock by increasing cardiac index without an effect on systemic vascular resistance index or PAOP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420733     DOI: 10.1097/00003246-199301000-00015

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

1.  The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock.

Authors:  David Di Giantomasso; Rinaldo Bellomo; Clive N May
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

2.  The Surviving Sepsis Campaign Bundle: 2018 update.

Authors:  Mitchell M Levy; Laura E Evans; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2018-04-19       Impact factor: 17.440

Review 3.  Sepsis and septic shock. II. Treatment.

Authors:  J Mayer; R Hajek; J Vorlicek; M Tomiska
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

Review 4.  Is the acute physiology and chronic health evaluation (APACHE) scale agist? Therapeutic implications in older patients.

Authors:  M Niskanen; L Niskanen
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

5.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2007-12-04       Impact factor: 17.440

Review 8.  Bench-to-bedside review: Is there a place for epinephrine in septic shock?

Authors:  Bruno Levy
Journal:  Crit Care       Date:  2005-11-04       Impact factor: 9.097

9.  Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock.

Authors:  Khaled M Mahmoud; Amany S Ammar
Journal:  Indian J Crit Care Med       Date:  2012-04

10.  Spectrofluorimetric estimation of norepinephrine using ethylenediamine condensation method.

Authors:  Mohammad Mainul Karim; Seikh Mafiz Alam; Sang Hak Lee
Journal:  J Fluoresc       Date:  2007-05-10       Impact factor: 2.525

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.